医疗公司报告了第四季度92%的收入增长,其SI联合融合系统获得FDA批准,2026年将获得430万美元的融资. Tenon Medical reported 92% Q4 revenue growth, FDA clearance for its SI joint fusion system, and a $4.3M funding round in 2026.

医疗公司报告了第四季度和2025年全年的强财务业绩,四季度收入同比增长92%至150万美元,全年收入达到3900万美元,20%的增加. Tenon Medical reported strong financial results for Q4 and full-year 2025, with fourth-quarter revenue rising 92% year-over-year to $1.5 million and full-year revenue reaching $3.9 million, a 20% increase. 公司的毛利率在第四季度升188%,达到100万美元,毛利幅度扩大至69%. Gross profit surged 188% to $1.0 million in Q4, with gross margin expanding to 69%. 该公司获得了FDA 510 ((k) 批准,用于其SImmetry®+ SI联合融合系统,使其能够进行侧面手术,并在2026年3月完成了一笔430万美元的高级可转换票据供应以支持增长. The company received FDA 510(k) clearance for its SImmetry®+ SI Joint Fusion System, enabling a lateral surgical approach, and completed a $4.3 million senior convertible note offering in March 2026 to support growth. 它还通过多项美国专利许可通知扩大了其知识产权组合,使其总数达到29个已发行的美国专业和31个待办的申请. It also expanded its IP portfolio with multiple U.S. patent Notices of Allowance, bringing its total to 29 issued U.S. patents and 31 pending applications.